Aduro will also pay the vendor a non-refundable fee of € 33,782 for the exclusive use of the property during the due ...
D-PLEX₁₀₀ has received Breakthrough Therapy Designation, three QIDP designations, and three Fast Track designations from the U.S. Food and Drug Administration. NDA submission is expected early 2026.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback